Altimmune, Inc. financial data

Symbol
ALT on Nasdaq
Industry
Pharmaceutical Preparations
Location
910 Clopper Road, Suite 201 S, Gaithersburg, Maryland
State of incorporation
Delaware
Fiscal year end
December 31
Former names
PHARMATHENE, INC (to 5/3/2017), HEALTHCARE ACQUISITION CORP (to 10/15/2007)
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.43K % +13.2%
Debt-to-equity 10.3 % -2.74%
Return On Equity -60.5 % -35%
Return On Assets -54.9 % -35.4%
Operating Margin -26.8K % -125%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 71.1M shares +34.9%
Common Stock, Shares, Outstanding 71M shares +34.9%
Entity Public Float 184M USD -65.7%
Common Stock, Value, Issued 7K USD +40%
Weighted Average Number of Shares Outstanding, Basic 70.9M shares +39.9%
Weighted Average Number of Shares Outstanding, Diluted 70.9M shares +39.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 409K USD -16.7%
Revenue from Contract with Customer, Excluding Assessed Tax 3.48M USD -44.2%
Research and Development Expense 77.9M USD +11.4%
General and Administrative Expense 19.8M USD +12.3%
Operating Income (Loss) -110M USD -25.2%
Nonoperating Income (Expense) 8.36M USD +36.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -20.7M USD +12.8%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -101M USD -24.6%
Earnings Per Share, Basic -1.63 USD/shares +2.4%
Earnings Per Share, Diluted -1.63 USD/shares +2.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 57.1M USD -44.2%
Assets, Current 171M USD +0.98%
Property, Plant and Equipment, Net 483K USD -45.2%
Operating Lease, Right-of-Use Asset 1.68M USD +246%
Intangible Assets, Net (Excluding Goodwill) 0 USD -100%
Other Assets, Noncurrent 1.68M USD +247%
Assets 173M USD -5.44%
Accounts Payable, Current 2.69M USD -33.4%
Employee-related Liabilities, Current 2.03M USD +16.1%
Liabilities, Current 15.2M USD +32.5%
Operating Lease, Liability, Noncurrent 1.52M USD +254%
Other Liabilities, Noncurrent 31K USD -40.4%
Liabilities 20.8M USD +33.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -5.19M USD -0.23%
Retained Earnings (Accumulated Deficit) -515M USD -24.5%
Stockholders' Equity Attributable to Parent 153M USD -9.05%
Liabilities and Equity 173M USD -5.44%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -16.4M USD +15.7%
Net Cash Provided by (Used in) Financing Activities -261K USD +13.6%
Net Cash Provided by (Used in) Investing Activities -39.5M USD -397%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 71M shares +34.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -56.1M USD -776%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 57.2M USD -44.2%
Deferred Tax Assets, Valuation Allowance 83M USD +44.9%
Deferred Tax Assets, Gross 83.1M USD +37.8%
Operating Lease, Liability 1.86M USD +106%
Depreciation 107K USD -14.4%
Payments to Acquire Property, Plant, and Equipment 51K USD +467%
Lessee, Operating Lease, Liability, to be Paid 2.4M USD
Property, Plant and Equipment, Gross 2.63M USD +1.82%
Operating Lease, Liability, Current 345K USD -27.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 376K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 422K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure +27.8%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 533K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 387K USD
Deferred Tax Assets, Operating Loss Carryforwards 54.1M USD +21.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Unrecognized Tax Benefits 711K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 398K USD
Operating Lease, Payments 100K USD 0%
Additional Paid in Capital 673M USD +14.7%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 119K USD +60.8%
Deferred Tax Assets, Net of Valuation Allowance 98K USD -96.8%
Share-based Payment Arrangement, Expense 13.1M USD +14.1%
Interest Expense 34K USD -50%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%